The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy. Nevertheless, a substantial number of patients fail to respond to checkpoint pathway blockade 1, 2 . β-catenin is the key transcriptional regulator of WNT/β-catenin signaling 3 .
Evidence for β-catenin-mediated immune evasion is found in 13% of all cancers 4 , 42% of primary cutaneous melanoma 5 and a mouse melanoma model 6 . Currently, there are no therapeutic strategies available for targeting WNT/β-catenin signaling to counteract checkpoint inhibitor resistance in melanoma. Here we report that a specific small-molecule tankyrase inhibitor, G007-LK [7] [8] [9] , attenuates WNT/β-catenin and YAP signaling pathways in the syngeneic murine B16-F10 melanoma model enabling sensitivity to anti-PD-1 immune checkpoint therapy. RNA sequencing of 18 tankyrase inhibitor-treated human melanoma cell lines and B16-F10 cells revealed a transcriptional response profile for a subpopulation. This cell line sub-group displayed elevated baseline YAP signaling activity and was susceptible to reduce melanocyte inducing transcription factor (MITF) expression upon tankyrase inhibition.
Checkpoint inhibitor treatment, including blockade of the PD-1 receptor, has shown limited efficacy against B16-F10 tumors despite strong expression of the ligand PD-L1 on the tumor cells 10 , a feature attributed to low infiltration by effector CD8 + T cells 11, 12 . G007-LK [7] [8] [9] is a potent and specific tankyrase inhibitor that obstructs WNT/β-catenin and YAP signaling through stabilization of the AXIN-based degradosome and AMOT proteins, respectively 8, [13] [14] [15] [16] [17] .
The efficacy of G007-LK treatment against WNT/β-catenin and YAP signaling in wild-type B16-F10 cells was explored in vitro and in vivo. Limited impact on proliferation was observed in cultured B16-F10 cells upon G007-LK treatment ( Supplementary Fig. 1a ). G007-LKtreated B16-F10 cells displayed a shift in TNKS1/2 gel-migration in vitro and formation of cytoplasmic TNKS1/2-containing puncta reflecting degradosome accumulation 8, 15, 18 ( Supplementary Fig. 1b,c) . In addition, G007-LK reduced the level of β-catenin protein and decreased transcription of WNT/β-catenin and YAP signaling target genes as well as luciferase-based reporter activities ( To test whether tankyrase inhibition can counteract resistance to PD-1 immune checkpoint blockade, subcutaneous B16-F10 tumors were established in C57BL/6N mice.
Monotherapy with G007-LK or anti-PD-1 resulted in no tumor size reduction, however, combined anti-PD-1/G007-LK treatment resulted in a significant reduction in tumor volume and weight ( Fig. 1c and Supplementary Fig. 3 ). In addition, a significant reduction in tumor volume was also observed upon combined anti-PD-1/G007-LK treatment of murine Clone M-3 Z1 melanoma in immunocompetent DBA/2N mice ( Fig. 1d and Supplementary Fig. 4 ). No signs of toxicity, intestinal injury ( Supplementary Fig. 3g ) or body weight changes were observed in any of the mouse experiments (Supplementary Fig. 3f and 4b ). To examine longer-term efficacy of combined anti-PD-1/G007-LK treatment, B16-F10-bearing C57BL/6N mice were followed until the entire control group reached the endpoint criterion.
In the 3 surviving anti-PD-1/G007-LK-treated mice (18.5%)( Fig. 1e and Supplementary Fig.   5 ), histopathological inspection of immunostained tumor sections detected no viable tumor cells. Instead, the tumor implant site was infiltrated by macrophages with ingested melanin, presumably derived from B16-F10 cells (Fig. 1f) . In summary, the tested murine melanoma models are resistant to single-agent anti-PD-1 or G007-LK treatment, however, a synergistic anti-tumor effect and eradication of a subset of the tumors was observed upon combined anti-PD-1/G007-LK treatment.
We next pursued the mechanistic basis for the observed synergy of anti-PD-1 and G007-LK treatment. To evaluate β-catenin-mediated immune evasion in the B16-F10 syngeneic mouse melanoma model, β-catenin was knocked out in B16-F10 cells (B16-
F10

Ctnnb1KO
, Supplementary Fig. 6 ) and the cell line was used to establish subcutaneous tumors in C57BL/6N mice. Compared to vehicle control, anti-PD-1-treated mice displayed significant reduction in tumor sizes, indicating loss of anti-PD-1 resistance in β-catenindeficient tumors ( Fig. 2a and Supplementary Fig. 7 ). The result suggests that the synergistic anti-PD-1/G007-LK treatment effect (Fig. 1c) can be attributed to G007-LK-induced reduction of β-catenin levels in β-catenin wild-type B16-F10 tumors (Fig. 1b) .
Previous work has demonstrated that decreased WNT/β-catenin signaling, in a genetically modified mouse melanoma model, promoted adaptive immune responses within the tumor by enhanced secretion of CCL4 6, 19 . The subsequent attraction of dendritic cells to the tumor site supported infiltration and activation of tumor-reactive CD8 + T cells 6 .
Dependency on T cells for the anti-PD-1/G007-LK synergy was evaluated using B16-F10-challenged CD8 + and CD4 + T cell-deficient Rag2 -/-mice 20 . No significant effect of anti-PD-1/G007-LK treatment was observed in Rag2 -/-mice, showing that the presence of T cells is required for the treatment effect ( Fig. 2b and Supplementary Fig. 8 ). To assess immune cell infiltration upon treatment, we performed flow cytometry analysis using tumors of comparable size collected on day 7-17 ( Supplementary Fig. 9a and 10) . A trend towards increased abundance of leukocytes was observed in the anti-PD-1-treated group, but not between the controls and the G007-LK or anti-PD-1/G007-LK-treated mice ( Supplementary   Fig. 9b ). An increase in total T cell and CD8 + T cell infiltration was seen in both the anti-PD-1 and anti-PD-1/G007-LK groups, whereas CD4 + T cells were similarly increased in all treatment groups ( Fig. 2c and Supplementary Fig. 9c ). No discernible differences in the abundance of CD4 + or CD8 + T cells expressing the memory marker CD44 was observed ( Supplementary Fig. 9d ). T regs constituted approximately 1% of infiltrating CD45 + cells in all groups ( Supplementary Fig. 9e ). Myeloid DCs were decreased in the anti-PD-1 and anti-PD-1/G007-LK-treated groups while CD103 + DCs were equally present in all treatment groups ( Supplementary Fig. 9f ). Lymphoid DCs, M-MDSC and neutrophils were present at comparable levels across all treatment groups ( Supplementary Fig. 9g ). A trend towards increased macrophage infiltration was observed in anti-PD-1/G007-LK-treated mice (Fig. 2d) .
Infiltration of M1-like macrophages was increased and M2-like macrophages decreased in the anti-PD-1 and anti-PD-1/G007-LK-treated groups leading to a decreased M2/M1 ratio ( Fig.   2d and Supplementary Fig. 9h ). In summary, combined anti-PD-1/G007-LK treatment of B16-F10 tumors confers a general T cell-dependent growth-inhibitory effect on B16-F10
tumors. Changes in myeloid DC, T cell and macrophage infiltrations are likely attributable to anti-PD-1 treatment but do not alone cause anti-tumor activity.
To identify alterations in CCL4 secretion upon G007-LK treatment, conditioned supernatants from matrigel-embedded B16-F10 tumors 21 and cell culture were screened using ELISA assays. Upon G007-LK treatment, CCL4 secretion was significantly reduced in B16-F10 tumors (Fig. 3a) while no significant CCL4 regulation was seen in cultivated B16-10 cells (Fig. 3b) . Ccl4 expression was not inversely correlated to its previously described negative regulator Atf3 6 in neither wild-type B16-F10 cells nor in B16-F10 Ctnnb1KO cells when compared to wild-type cells (Fig. 3a,b ). In conclusion, the anti-PD-1/G007-LK-induced antitumor efficacy observed herein is independent from enhanced CCL4 secretion.
B16-F10 murine melanoma, lacking the BRAF V600E mutation 22, 23 , only partially recapitulates the genetic features of human melanoma. Thus, murine B16-F10 cells, and a panel of 18 human melanoma cell lines, were exposed to G007-LK treatment followed by RNA sequencing and bioinformatic analyses. In the untreated group, no clear correlation was found between baseline transcription of WNT/β-catenin signaling target genes or the mutation load, including BRAF V600E , against overall gene expression (Supplementary Fig. 11a and 12 ).
However, when the cell lines were classified into two groups based on baseline YAP signaling target gene transcription, YAP high and YAP low (Fig. 4a) , the YAP high group coincided with clustering of overall gene expression and against a panel of markers for β-catenin-controlled melanoma cell fate and proliferation 24 ( Supplementary Fig. 11 Supplementary Fig. 15a ). In B16-F10 tumors, transcription of Mitf was reduced upon G007-LK-treatment (Fig. 4c) . Attenuated WNT/β-catenin and/or YAP signaling activity was observed in nearly all samples upon G007-LK treatment, but did not correlate with changes in MITF expression, nor act as a predictive marker for MITF regulation (Fig. 4d ,e and Supplementary Fig. 15 and 16 ). In conclusion, YAP high is a marker for a melanoma sub-group that includes B16-F10 and tracks with tankyrase inhibitor-induced reduction in MITF expression ( Fig. 4e and Supplementary Fig. 17 ).
WNT/β-catenin signaling plays a central role, not only in regulation of immune cell homeostasis, development and function, but also impacts circulating immune cells, -including control of peripheral T cell activation, differentiation and tumor-immune cell interplay 19 . Active YAP signaling may support immune evasion in cancer and melanoma by inducing PD-L1 expression 28, 29 ( Supplementary Fig. 18 ) while another report shows that enhanced YAP signaling, due to loss of LATS1/2, may promote anti-cancer immune response 30 . Tankyrase inhibition also leads to regulation of the complex network of cytokines and chemokines, which conceivably may influence myeloid cell anti-tumor activity 31 ( Fig. 3 and Supplementary Fig. 19 ). Presently, neither the meeting points between MITF, its regulation by YAP/TAZ/TEAD, AP-1 and tankyrase, nor the function in immune regulation and control of susceptibility to checkpoint-inhibitor therapy are well characterized 27, [32] [33] [34] [35] [36] .
Collectively, the results presented herein suggest that G007-LK-induced blockade of WNT/β- RNA isolation and real-time qRT-PCR. Total RNA was isolated from treated cell lines and tumor samples using GenEluteTM Mammalian Total RNA Miniprep Kit (Sigma Aldrich).
The RNA concentration was measured using Nanodrop 2000c spectrophotometer (Thermo Scientific). cDNA was synthesized from the purified RNA using SuperScript TM VILO cDNA Synthesis Kit (Invitrogen). Real-time qRT-PCR (TaqMan®Gene Expression system, Applied
Biosystems) was performed using Viia7 (Applied Biosystems). The following probes were used (all from Applied Biosystems):
Proliferation assays. 1000 cells/well were seeded in 96-well plates using minimum 6
replicates for each treatment tested. The day after, cell culture medium was changed to contain various doses of G007-LK or vehicle (DMSO, Sigma Aldrich) and the plates were 
Immunofluorescent staining and Structured Illumination Microscopy (SIM).
Cells grown on coverslips pre-coated with poly-L-lysine (sc-286689, Santa Cruz Biotechnology)
were fixed in 4% paraformaldehyde (P6148, Sigma Aldrich, 15 minutes at room temperature) and permeabilized with 0.1% Triton-X100/PBS (T8787, Sigma Aldrich, 15 minutes at room temperature) followed by 1 hour incubations with primary and secondary antibodies diluted in PBS with 4% bovine serum albumin, both at room temperature. Nuclear counterstaining was performed with DAPI (D9542, Sigma Aldrich, 1 μg/mL, 5 minutes at room temperature) and coverslips were mounted in ProLong Diamond Antifade Mountant (Thermo Fisher Scientific).
The following primary antibodies and dilutions were used: β-catenin (BD610153, 1:500, BD Biosciences) and Tankyrase were randomized into 2 groups (n = 12), and treatments i) and v) were administered to the respective mice. On day 20, the animals were euthanized. 1 mouse from treatment group i) and 2 mice from treatment group v) were euthanized for ethical reasons before experiment termination, due to skin ulcerations in the tumor area or excessive tumor size.
Survival assay using B16-F10 cells in C57BL/6N mice: 60 animals with primary tumors reaching 20-100 mm 3 were randomized into 2 groups (n = 30, control or G007-LK and anti-PD-1). The survival assay endpoint criterion was set to tumor volume >1000 mm 3 Bioinformatics. Transcripts were quantified with kallisto (v0.44) 41 using ensembl transcriptome release 91 for human (GRCh38) and release 92 for mouse (GRCm38) 42 .
Ensemble BioMart was used to map human orthologs in mouse 41 . Differentially expressed genes (DEGs) were identified with sleuth (v0.29) 43 , limma 44 Data availability. The RNA sequencing data for this study is available from ArrayExpress (available to reviewers upon request) with accession xxx for the mouse experiment (fastq and processed) and with accession xxx for the human experiment (processed). Supplementary   Figures 1-19 are available online. Any additional data generated and analyzed in this study are available from the corresponding author upon reasonable request.
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